RANKL signaling and osteoclastogenesis is negatively regulated by cardamonin.
Bone loss/resorption or osteoporosis is a disease that is accelerated with aging and age-associated chronic diseases such as cancer. Bone loss has been linked with human multiple myeloma, breast cancer, and prostate cancer and is usually treated with bisphosphonates, and recently approved denosumab,...
Guardado en:
Autores principales: | Bokyung Sung, Sahdeo Prasad, Vivek R Yadav, Subash C Gupta, Simone Reuter, Norio Yamamoto, Akira Murakami, Bharat B Aggarwal |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2071b5fa832d4673bf4012e1fc9c25ac |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Perillaldehyde inhibits bone metastasis and receptor activator of nuclear factor-κB ligand (RANKL) signaling-induced osteoclastogenesis in prostate cancer cell lines
por: Zhuoyuan Lin, et al.
Publicado: (2021) -
KMUP-1 suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss: roles of MAPKs, Akt, NF-κB and calcium/calcineurin/NFATc1 pathways.
por: Shu-Fen Liou, et al.
Publicado: (2013) -
Gα13 negatively controls osteoclastogenesis through inhibition of the Akt-GSK3β-NFATc1 signalling pathway
por: Mengrui Wu, et al.
Publicado: (2017) -
RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway
por: Mineon Park, et al.
Publicado: (2021) -
RANKL regulates male reproductive function
por: Martin Blomberg Jensen, et al.
Publicado: (2021)